References of "Bouvenot, G"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailAdherence to treatment of osteoporosis: a need for study
Lekkerkerker, F.; Kanis, J. A.; Alsayed, N. et al

in Osteoporosis International (2007), 18(10), 1311-1317

Adherence to anti-osteoporosis medications is currently low and is associated with poor anti-fracture efficacy. This manuscript reviews the potential design of clinical studies that aim to demonstrate ... [more ▼]

Adherence to anti-osteoporosis medications is currently low and is associated with poor anti-fracture efficacy. This manuscript reviews the potential design of clinical studies that aim to demonstrate improved adherence, with new chemical entities to be used in the management of osteoporosis. Introduction Several medications have been unequivocally shown to decrease fracture rates in clinical trials. However, in real life settings, long-term persistence and compliance to anti-osteoporosis medication is poor, hence decreasing the clinical benefits for patients. Methods An extensive search of Medline from 1985 to 2006 retrieved all trials including the keywords osteoporosis, compliance, persistence or adherence followed by a critical appraisal of the data obtained through a consensus expert meeting. Results The impact of non-adherence on the clinical development of interventions is reviewed, so that clinicians, regulatory agencies and reimbursement agencies might be better informed of the problem, in order to stimulate the necessary research to document adherence. Conclusion Adherence to therapy is a major problem in the treatment of osteoporosis. Both patients and medication factors are involved. Adherence studies are an important aspect of outcomes studies, but study methodologies are not well developed at the moment and should be improved. Performing adherence studies will be stimulated when registration authorities accept the result of these studies and include the relevant information in Sect. 5.1 of the summary of product characteristics. Reimbursement authorities might also consider such studies as important information for decisions on reimbursement. [less ▲]

Detailed reference viewed: 33 (2 ULg)
Full Text
Peer Reviewed
See detailTotal joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis
Altman, R. D.; Abadie, Eric ULg; Avouac, B. et al

in Osteoporosis International (2005, March), 16(Suppl.3), 10

Detailed reference viewed: 32 (2 ULg)
Full Text
Peer Reviewed
See detailRecommendations for the registration of agents used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from GREES
Abadie, Eric ULg; Devogealer, Jean-Pierre; Ringe, J. et al

in Osteoporosis International (2005, March), 16(Suppl.3), 47

Detailed reference viewed: 14 (1 ULg)
Full Text
Peer Reviewed
See detailTotal joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis
Altman, R. D.; Abadie, Eric ULg; Avouac, B. et al

in Osteoarthritis and Cartilage (2005), 13(1), 13-19

Objective: The Group for the Respect of Ethics and Excellence in Science (GREES) organized a working group to assess the value of time to joint surgery as a potential therapeutic failure outcome criterion ... [more ▼]

Objective: The Group for the Respect of Ethics and Excellence in Science (GREES) organized a working group to assess the value of time to joint surgery as a potential therapeutic failure outcome criterion for osteoarthritis (OA) of the hip or knee in the assessment of potential structure modifying agents. Methods: PubMed was searched for manuscripts from 1976 to 2004. Relevant studies were discussed at a 1-day meeting. Results: There are no accepted guidelines for 'time to' and 'indications for' joint replacement surgery. A limited number of trials have examined joint replacement surgery within the study population. Several parameters, particularly joint space narrowing (interbone distance), correlate with surgical intervention. However, at the level of the knee, none of the parameters have positive predictive value for joint replacement surgery better than 30%. In contrast, lack of significant joint space narrowing has a strong negative predictive value for joint replacement surgery (> 90%), that remains after controlling for OA pain severity. Conclusion: At this time, GREES cannot recommend time to joint surgery as a primary endpoint of failure for structure modifying trials of hip or knee OA-as the parameter has sensitivity but lacks specificity. In contrast, in existing trials, a lack of progression of joint space narrowing has predictive value of > 90% for not having surgery. GREES suggests utilizing joint space narrowing (e.g., > 0.3-0.7 mm) combined with a lack of clinically relevant improvement in symptoms (e.g., greater than or equal to 20-25%) for 'failure' of a secondary outcome in structure modifying trials of the hip and knee. (C) 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved. [less ▲]

Detailed reference viewed: 68 (10 ULg)
Full Text
Peer Reviewed
See detailTime dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach
Richy, F.; Bruyère, Olivier ULg; Ethgen, Olivier ULg et al

in Annals of the Rheumatic Diseases (2004), 63(7), 759-766

OBJECTIVES: To provide an updated document assessing the global, NSAID-specific, and time dependent risk of gastrointestinal (GI) complications through meta-analyses of high quality studies. METHODS: An ... [more ▼]

OBJECTIVES: To provide an updated document assessing the global, NSAID-specific, and time dependent risk of gastrointestinal (GI) complications through meta-analyses of high quality studies. METHODS: An exhaustive systematic search was performed. Inclusion criteria were: RCT or controlled study, duration of 5 days at least, inactive control, assessment of minor or major NSAID adverse effects, publication range January 1985 to January 2003. The publications retrieved were assessed during a specifically dedicated WHO meeting including leading experts in all related fields. Statistics were performed conservatively. Meta-regression was performed by regressing NSAID adjusted estimates against study duration categories. RESULTS: Among RCT data, indolic derivates provided a significantly higher risk of GI complications related to NSAID use than for non-users: RR = 2.25 (1.00; 5.08) than did other compounds: naproxen: RR = 1.83 (1.25; 2.68); diclofenac: RR = 1.73 (1.21; 2.46); piroxicam: RR = 1.66 (1.14; 2.44); tenoxicam: RR = 1.43 (0.40; 5.14); meloxicam: RR = 1.24 (0.98; 1.56), and ibuprofen: RR = 1.19 (0.93; 1.54). Indometacin users had a maximum relative risk for complication at 14 days. The other compounds presented a better profile, with a maximum risk at 50 days. Significant additional risk factors included age, dose, and underlying disease. The controlled cohort studies provided higher estimates: RR = 2.22 (1.7; 2.9). Publication bias testing was significant, towards a selective publication of deleterious effects of NSAIDs from small sized studies. CONCLUSION: This meta-analysis characterised the "compound" and "time" aspects of the GI toxicity of non-selective NSAIDs. The risk/benefit ratio of such compounds should thus be carefully and individually evaluated at the start of long term treatment. [less ▲]

Detailed reference viewed: 48 (10 ULg)
Full Text
Peer Reviewed
See detailTime-dependent risk of gastrointestinal complications induced by NSAIDS use: a consensus statement using meta-analytic approach
Richy, Florent; Bruyère, Olivier ULg; Ethgen, Olivier ULg et al

in Osteoporosis International (2003, November), 14(Suppl. 7), 9

Detailed reference viewed: 15 (3 ULg)
Full Text
Peer Reviewed
See detailDo new methods of investigation allow faster assessment of drugs efficacy in osteoarthritis?
Abadie, Eric ULg; Avouac, B.; Bouvenot, G. et al

in Osteoporosis International (2003, November), 14(Suppl. 7), 2

Detailed reference viewed: 16 (2 ULg)
Full Text
Peer Reviewed
See detailGuidelines for clinical studies assessing the efficacy of drugs for the management of acute low back pain
Devogelaer, J. P.; Dreiser, R. L.; Abadie, Eric ULg et al

in Clinical and Experimental Rheumatology (2003), 21(6, NOV-DEC), 691-694

In this paper we propose guidelines for clinical trials aimed at assessing the efficacy of drugs for acute non-specific low back pain (LBP) with or without radicular pain, preliminary to their approval ... [more ▼]

In this paper we propose guidelines for clinical trials aimed at assessing the efficacy of drugs for acute non-specific low back pain (LBP) with or without radicular pain, preliminary to their approval and registration. To this end, consensus statements were obtained from a group of experts in the fields of rheumatology, clinical medicine, public health and epidemiology. EBM resources were systematically used as references. [less ▲]

Detailed reference viewed: 20 (3 ULg)
Full Text
Peer Reviewed
See detailDo estrogens effectively prevent osteoporosis-related fractures?
Reginster, Jean-Yves ULg; Bruyère, Olivier ULg; Audan, M. et al

in Calcified Tissue International (2000), 67

Detailed reference viewed: 12 (6 ULg)
Full Text
Peer Reviewed
See detailRecommendations for the registration of drugs used in the treatment of rheumatoid arthritis
Lemmel, EM; Reid, DM; Nuki, G et al

in British Journal of Rheumatology (1998), 37

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailRecommendations for the registration of agents used in the prevention and treatment of glucocorticoid-induced osteoporosis
Compston, JE; Audran, M; Avouac, B et al

in Calcified Tissue International (1996), 59

Detailed reference viewed: 12 (1 ULg)
Full Text
Peer Reviewed
See detailRecommendations for registration of drugs used in the treatment of osteoarthritis
Dougados, M; Devogelaer, JP; Annefeldt, M et al

in Annals of the Rheumatic Diseases (1996), 55

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailRecommendations for the registration of new chemical entities used in the prevention and treatment of osteoporosis
Reginster, Jean-Yves ULg; Compston, JE; Jones, EA et al

in Calcified Tissue International (1995), 57

Detailed reference viewed: 20 (2 ULg)